REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Wang YN, Chen ZH, Chen WC. Novel circulating microRNAs expression profile in colon cancer: a pilot study. Eur J Med Res 2017;22:51.
3. Chen B, Xia Z, Deng YN, et al. Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. Open Biol 2019;9:180212.
4. Campos FGCM, Figueiredo MN, Monteiro M, Nahas SC, Cecconello I. Incidence of colorectal cancer in young patients. Rev Col Bras Cir 2017;44:208-15.
5. Yang J, Yu J. The association of diet, gut microbiota and colorectal cancer: what we eat may imply what we get. Protein Cell 2018;9:474-87.
6. Bailey CE, Hu CY, You YN, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 2015;150:17-22.
7. Campos FG, Figueiredo MN, Martinez CA. Colorectal cancer risk in hamartomatous polyposis syndromes. World J Gastrointest Surg 2015;7:25-32.
8. Schlussel AT, Gagliano RA Jr, Seto-Donlon S, et al. The evolution of colorectal cancer genetics-Part 1: from discovery to practice. J Gastrointest Oncol 2014;5:326-35.
9. Simard J, Kamath S, Kircher S. Survivorship guidance for patients with colorectal cancer. Curr Treat Options Oncol 2019;20:38.
10. Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol 2012;3:153-73.
11. Dimitrakopoulou-Strauss A, Ronellenfitsch U, Cheng C, et al. Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clin Transl Imaging 2017;5:183-97.
12. Tevlin R, Larkin JO, Hyland JM, O'Connell PR, Winter DC. Primary colorectal lymphoma - a single centre experience. Surgeon 2015;13:151-5.
13. Beaton C, Davies M, Beynon J. The management of primary small bowel and colon lymphoma--a review. Int J Colorectal Dis 2012;27:555-63.
16. Salyers WJ, Vega KJ, Munoz JC, Trotman BW, Tanev SS. Neuroendocrine tumors of the gastrointestinal tract: case reports and literature review. World J Gastrointest Oncol 2014;6:301-10.
17. Degnan AJ, Tocchio S, Kurtom W, Tadros SS. Pediatric neuroendocrine carcinoid tumors: management, pathology, and imaging findings in a pediatric referral center. Pediatr Blood Cancer 2017;64:e26477.
18. Busbait S, Al-babtain A, Tawfeeq Y, Aljehani Y, Al-buainain H. Turcot's syndrome presenting as an acute abdomen. J Pediatr Surg Case Rep 2019;40:17-9.
19. Lebrun C, Olschwang S, Jeannin S, Vandenbos F, Sobol H, Frenay M. Turcot syndrome confirmed with molecular analysis. Eur J Neurol 2007;14:470-2.
20. Daniell J, Plazzer JP, Perera A, Macrae F. An exploration of genotype-phenotype link between Peutz-Jeghers syndrome and STK11: a review. Fam Cancer 2018;17:421-7.
21. Tan H, Mei L, Huang Y, et al. Three novel mutations of STK11 gene in Chinese patients with Peutz-Jeghers syndrome. BMC Med Genet 2016;17:77.
22. Chen HY, Jin XW, Li BR, et al. Cancer risk in patients with Peutz-Jeghers syndrome: a retrospective cohort study of 336 cases. Tumour Biol 2017;39:1010428317705131.
23. Qiu Y, Xuan T, Yin M, et al. Clinical characteristics and genetic analysis of gene mutations in a Chinese pedigree with Peutz-Jeghers syndrome. Clin Case Rep 2019;7:735-9.
24. Armelao F, de Pretis G. Familial colorectal cancer: a review. World J Gastroenterol 2014;20:9292-8.
25. Rosty C. The role of the surgical pathologist in the diagnosis of gastrointestinal polyposis syndromes. Adv Anat Pathol 2018;25:1-13.
26. Jaoude JB, Hallit R, Rassy EE, Abboud B. The role of prophylactic gastrectomy in patients with juvenile polyposis syndrome. Clin Res Hepatol Gastroenterol 2019;43:e42-3.
27. Sur D, Colceriu M, Sur G, Floca E, Dascal L, Irimie A. Colorectal cancer: evolution of screening strategies. Med Pharm Rep 2019;92:21-4.
28. Wender RC, Brawley OW, Fedewa SA, Gansler T, Smith RA. A blueprint for cancer screening and early detection: advancing screening's contribution to cancer control. CA Cancer J Clin 2019;69:50-79.
29. Hadjipetrou A, Anyfantakis D, Galanakis CG, Kastanakis M, Kastanakis S. Colorectal cancer, screening and primary care: a mini literature review. World J Gastroenterol 2017;23:6049-58.
31. Kościelniak-Merak B, Radosavljević B, Zając A, Tomasik PJ. Faecal occult blood point-of-care tests. J Gastrointest Cancer 2018;49:402-5.
32. Berry E, Miller S, Koch M, Balasubramanian B, Argenbright K, Gupta S. Lower abnormal fecal immunochemical test cut-off values improve detection of colorectal cancer in system-level screens. Clin Gastroenterol Hepatol 2020;18:647-53.
33. Dollinger MM, Behl S, Fleig WE. Early Detection of colorectal cancer: a multi-center pre-clinical case cohort study for validation of a combined DNA stool test. Clin Lab 2018;64:1719-30.
34. Vacante M, Borzì AM, Basile F, Biondi A. Biomarkers in colorectal cancer: current clinical utility and future perspectives. World J Clin Cases 2018;6:869-81.
35. Leung WC, Foo DC, Chan TT, et al. Alternatives to colonoscopy for population-wide colorectal cancer screening. Hong Kong Med J 2016;22:70-7.
36. El Zoghbi M, Cummings LC. New era of colorectal cancer screening. World J Gastrointest Endosc 2016;8:252-8.
37. Kroijer R, Kobaek-Larsen M, Qvist N, Knudsen T, Baatrup G. Colon capsule endoscopy for colonic surveillance. Colorectal Dis 2019;21:532-7.
38. Milluzzo SM, Bizzotto A, Cesaro P, Spada C. Colon capsule endoscopy and its effectiveness in the diagnosis and management of colorectal neoplastic lesions. Expert Rev Anticancer Ther 2019;19:71-80.
39. Miller EA, Pinsky PF, Schoen RE, Prorok PC, Church TR. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial. Lancet Gastroenterol Hepatol 2019;4:101-10.
40. Segev L, Kalady MF, Church JM. Left-sided dominance of early-onset colorectal cancers: a rationale for screening flexible sigmoidoscopy in the young. Dis Colon Rectum 2018;61:897-902.
41. Quero G, Galiandro F, Hassan C, et al. Colonoscopy quality assessment and accuracy: analysis of the influencing factors and surgical sequelae on 216 colonoscopies. Eur Rev Med Pharmacol Sci 2019;23:2532-8.
42. Hernández G, Gimeno-García AZ, Quintero E. Strategies to optimise the quality of bowel cleansing. Gastroenterol Hepatol 2019;42:326-38.
43. Zhang Q, Wang XQ, Wang J, et al. Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients. Oncotarget 2015;6:15095-110.
44. Nahacka Z, Svadlenka J, Peterka M, et al. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor. Biochim Biophys Acta Mol Cell Res 2018;1865:522-31.
45. Mehta RS, Chong DQ, Song M, et al. Association between plasma levels of macrophage inhibitory cytokine-1 before diagnosis of colorectal cancer and mortality. Gastroenterology 2015;149:614-22.
46. Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R. DNA methylation based biomarkers in colorectal cancer: a systematic review. Biochim Biophys Acta 2016;1866:106-20.
47. Graule J, Uth K, Fischer E, et al. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clin Epigenetics 2018;10:120.
48. Ren A, Dong Y, Tsoi H, Yu J. Detection of miRNA as non-invasive biomarkers of colorectal cancer. Int J Mol Sci 2015;16:2810-23.
49. Iwakawa HO, Tomari Y. The functions of microRNAs: mRNA decay and translational repression. Trends Cell Biol 2015;25:651-65.
50. Ruebel K, Leontovich AA, Stilling GA, et al. MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression. Mod Pathol 2010;23:367-75.
51. Mitsuhashi K, Yamamoto I, Kurihara H, et al. Analysis of the molecular features of rectal carcinoid tumors to identify new biomarkers that predict biological malignancy. Oncotarget 2015;6:22114-25.
52. Li SC, Essaghir A, Martijn C, et al. Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors. Mod Pathol 2013;26:685-96.
53. Fan R, Zhong J, Zheng S, et al. microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway. Clin Exp Med 2015;15:137-44.
54. Cao CL, Niu HJ, Kang SP, Cong CL, Kang SR. MiRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to imatinib via targeting B-cell lymphoma 2 (Bcl-2). Eur Rev Med Pharmacol Sci 2016;20:3574-81.
55. Kim WK, Park M, Kim YK, et al. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin Cancer Res 2011;17:7584-94.
56. Wang Y, Li J, Kuang D, et al. miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT. Cell Commun Signal 2018;16:16.
57. Niinuma T, Kai M, Kitajima H, et al. Downregulation of miR-186 is associated with metastatic recurrence of gastrointestinal stromal tumors. Oncol Lett 2017;14:5703-10.
58. Ihle MA, Trautmann M, Kuenstlinger H, et al. miRNA-221 and miRNA-222 induce apoptosis via the KIT/AKT signalling pathway in gastrointestinal stromal tumours. Mol Oncol 2015;9:1421-33.
59. Yamamoto H, Kohashi K, Fujita A, Oda Y. Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromal tumor. Mod Pathol 2013;26:563-71.
60. Liu S, Cui J, Liao G, et al. MiR-137 regulates epithelial-mesenchymal transition in gastrointestinal stromal tumor. Tumour Biol 2014;35:9131-8.
61. Shi Y, Gao X, Hu Q, et al. PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor. Lab Invest 2016;96:652-60.
62. Lu HJ, Yan J, Jin PY, et al. MicroRNA-152 inhibits tumor cell growth while inducing apoptosis via the transcriptional repression of cathepsin L in gastrointestinal stromal tumor. Cancer Biomark 2018;21:711-22.
63. Knudsen KN, Nielsen BS, Lindebjerg J, Hansen TF, Holst R, Sørensen FB. microRNA-17 is the most up-regulated member of the miR-17-92 cluster during early colon cancer evolution. PLoS One 2015;10:e0140503.
64. Hu J, Xu Y, Cai S. Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma. Eur J Med Res 2015;20:95.
65. Wang JY, Wang CL, Wang XM, Liu FJ. Comprehensive analysis of MicroRNA/MRNA signature in colon adenocarcinoma. Eur Rev Med Pharmacol Sci 2017;21:2114-29.
66. Perilli L, Vicentini C, Agostini M, et al. Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression. Oncotarget 2014;5:6611-9.
67. Aslam MI, Hussein S, West K, Singh B, Jameson JS, Pringle JH. MicroRNAs associated with initiation and progression of colonic polyp: a feasibility study. Int J Surg 2015;13:272-9.
68. Nagy ZB, Wichmann B, Kalmár A, et al. Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens. Clin Epigenetics 2017;9:22.
69. Sun CM, Luan CF. Overexpression of microRNA-21 in peripheral blood mononuclear cells of patients with B-cell non-Hodgkin's lymphoma is associated with disease stage and treatment outcome. Eur Rev Med Pharmacol Sci 2015;19:3397-402.
70. Takei Y, Ohnishi N, Kisaka M, Mihara K. Determination of abnormally expressed microRNAs in bone marrow smears from patients with follicular lymphomas. Springerplus 2014;3:288.
71. Yuan WX, Gui YX, Na WN, Chao J, Yang X. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. Oncol Lett 2016;11:423-32.
72. Cui Q, Vari F, Cristino AS, et al. Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma. Oncotarget 2018;9:34644-57.
73. Bartolomé-Izquierdo N, de Yébenes VG, Álvarez-Prado AF, et al. miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma. Blood 2017;129:2408-19.
74. Anvarnia A, Mohaddes-Gharamaleki F, Asadi M, Akbari M, Yousefi B, Shanehbandi D. Dysregulated microRNAs in colorectal carcinogenesis: new insight to cell survival and apoptosis regulation. J Cell Physiol 2019;234:21683-93.
75. To KK, Tong CW, Wu M, Cho WC. MicroRNAs in the prognosis and therapy of colorectal cancer: from bench to bedside. World J Gastroenterol 2018;24:2949-73.
76. Ding J, Zhao Z, Song J, Luo B, Huang L. MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7. Acta Biochim Biophys Sin (Shanghai) 2018;50:597-604.
77. Wu QB, Sheng X, Zhang N, Yang MW, Wang F. Role of microRNAs in the resistance of colorectal cancer to chemoradiotherapy. Mol Clin Oncol 2018;8:523-7.
78. Subramanian S, Lui WO, Lee CH, et al. MicroRNA expression signature of human sarcomas. Oncogene 2008;27:2015-26.
79. Kelly L, Bryan K, Kim SY, et al. NIH Pediatric and Wild-Type GIST Clinic. Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]. PLoS One 2013;8:e64102.
80. Akçakaya P, Caramuta S, Åhlen J, et al. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer 2014;111:2091-102.
81. Khoury S, Tran N. Circulating microRNAs: potential biomarkers for common malignancies. Biomark Med 2015;9:131-51.
82. Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol 2019;20:5-20.
83. Carter JV, Galbraith NJ, Yang D, Burton JF, Walker SP, Galandiuk S. Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis. Br J Cancer 2017;116:762-74.
84. Germano G, Mauri G, Siravegna G, et al. Parallel evaluation of circulating tumor DNA and circulating tumor cells in metastatic colorectal cancer. Clin Colorectal Cancer 2018;17:80-3.
85. Liu HN, Liu TT, Wu H, et al. Serum microRNA signatures and metabolomics have high diagnostic value in colorectal cancer using two novel methods. Cancer Sci 2018;109:1185-94.
86. Liu HN, Wu H, Tseng YJ, et al. Serum microRNA signatures and metabolomics have high diagnostic value in gastric cancer. BMC Cancer 2018;18:415.
87. Toiyama Y, Okugawa Y, Fleshman J, Richard Boland C, Goel A. MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: a systematic review. Biochim Biophys Acta Rev Cancer 2018;1870:274-82.
88. Du B, Wu D, Yang X, et al. The expression and significance of microRNA in different stages of colorectal cancer. Medicine (Baltimore) 2018;97:e9635.
89. Vychytilova-Faltejskova P, Radova L, Sachlova M, et al. Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. Carcinogenesis 2016;37:941-50.
90. Yang J, Ma D, Fesler A, et al. Expression analysis of microRNA as prognostic biomarkers in colorectal cancer. Oncotarget 2017;8:52403-12.
91. Ogata-Kawata H, Izumiya M, Kurioka D, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One 2014;9:e92921.
92. Jacob H, Stanisavljevic L, Storli KE, Hestetun KE, Dahl O, Myklebust MP. Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. Oncotarget 2017;8:87837-47.
93. Coebergh van den Braak RRJ, Sieuwerts AM, Lalmahomed ZS, et al; MATCH study group*. Confirmation of a metastasis-specific microRNA signature in primary colon cancer. Sci Rep 2018;8:5242.
94. Jacob H, Stanisavljevic L, Storli KE, Hestetun KE, Dahl O, Myklebust MP. A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer. Sci Rep 2018;8:6157.
95. Zhu M, Huang Z, Zhu D, et al. A panel of microRNA signature in serum for colorectal cancer diagnosis. Oncotarget 2017;8:17081-91.
96. Zhang H, Zhu M, Shan X, et al. A panel of seven-miRNA signature in plasma as potential biomarker for colorectal cancer diagnosis. Gene 2019;687:246-54.
97. Wikberg ML, Myte R, Palmqvist R, van Guelpen B, Ljuslinder I. Plasma miRNA can detect colorectal cancer, but how early? Cancer Med 2018;7:1697-705.
98. Karimi N, Ali Hosseinpour Feizi M, Safaralizadeh R, et al. Serum overexpression of miR-301a and miR-23a in patients with colorectal cancer. J Chin Med Assoc 2019;82:215-20.
99. Liu X, Xu X, Pan B, et al. Circulating miR-1290 and miR-320d as novel diagnostic biomarkers of human colorectal cancer. J Cancer 2019;10:43-50.
100. Yang Q, Wang S, Huang J, Xia C, Jin H, Fan Y. Serum miR-20a and miR-486 are potential biomarkers for discriminating colorectal neoplasia: a pilot study. J Cancer Res Ther 2018;14:1572-7.
101. Chang PY, Chen CC, Chang YS, et al. MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection. Oncotarget 2016;7:10663-75.
102. Zhou X, Wen W, Shan X, et al. A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis. Oncotarget 2017;8:6513-25.
103. Monzo M, Santasusagna S, Moreno I, et al. Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer. Oncotarget 2017;8:30859-69.
104. Montagnana M, Benati M, Danese E, et al. Plasma expression levels of circulating miR-21 are not useful for diagnosing and monitoring colorectal cancer. Clin Lab 2016;62:967-70.
105. Micallef I, Baron B. The mechanistic roles of ncRNAs in promoting and supporting chemoresistance of colorectal cancer. Noncoding RNA 2021;7:24.
106. Sasaki M, Ishikawa T, Ishiguro M, et al. The effectiveness of plasma miR-33a-5p as a predictive biomarker for the efficacy of colorectal cancer chemotherapy. Oncol Lett 2021;21:489.
107. Li J, Mo R, Zheng L. MicroRNA-490-3p inhibits migration and chemoresistance of colorectal cancer cells via targeting TNKS2. World J Surg Oncol 2021;19:117.
